2019) Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview, Artificial ABSTRACT Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin TM , Lipoplatin TM and SPI-077 are PEGylated liposomebased nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP. ARTICLE HISTORY Current status of FDA-approved/under clinical trials CDDP nano-formulationsMany liposomal-based nano-formulations are at the stage of clinical trials. One of under clinical trials drugs, Lipoplatin (Regulon, Inc.), is liposome-based platinum formulation under Phase III clinical trials [11]. It contains a combination of cisplatin (9%) and lipids (91%(w/w)), including soy phosphatidylcholine (SPC-3), cholesterol, dipalmitoyl phosphatidyl glycerol (DPPG) and methoxy-PEG-distearoyl phosphatidyl

No abstract

No abstract

Natural polymers have been extensively utilized in the past decades due to their outstanding features. Among these natural excipients, protein‐based polymers have superb features owing to their high drug binding capacity and biodegradability. Whey protein is a versatile protein‐based vehicle for drug delivery systems. It has been shown to be nontoxic, biocompatible, and biodegradable. Therefore, it has been considered as an ideal biomaterial for the design of advanced drug delivery systems. Protein‐based cargo acts as synthetic polymers counterpart for innovative delivery systems. The current review is mainly focused on application of whey proteins as an emerging carrier in drug delivery systems, achieved during the past.